FY2018 EPS Estimates for Iovance Biotherapeutics Inc (IOVA) Boosted by Analyst

Iovance Biotherapeutics Inc (NASDAQ:IOVA) – Equities research analysts at Jefferies Financial Group upped their FY2018 earnings per share estimates for Iovance Biotherapeutics in a report issued on Tuesday, November 6th. Jefferies Financial Group analyst B. Amin now forecasts that the biotechnology company will earn ($1.29) per share for the year, up from their prior estimate of ($1.35). Jefferies Financial Group also issued estimates for Iovance Biotherapeutics’ Q4 2018 earnings at ($0.29) EPS, FY2019 earnings at ($1.11) EPS, FY2020 earnings at ($1.35) EPS, FY2021 earnings at ($0.50) EPS and FY2022 earnings at $1.31 EPS.

Several other equities analysts also recently weighed in on IOVA. Zacks Investment Research raised shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Tuesday, July 17th. HC Wainwright set a $22.00 price target on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research report on Tuesday, August 7th. BidaskClub lowered shares of Iovance Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 28th. Citigroup raised their price objective on shares of Iovance Biotherapeutics from $22.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, October 12th. Finally, Cowen reiterated a “buy” rating on shares of Iovance Biotherapeutics in a research note on Tuesday, November 6th. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. Iovance Biotherapeutics has an average rating of “Buy” and a consensus price target of $23.75.

IOVA opened at $8.97 on Friday. The firm has a market cap of $874.67 million, a price-to-earnings ratio of -6.36 and a beta of 3.03. Iovance Biotherapeutics has a 52-week low of $7.40 and a 52-week high of $19.90.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.03).

Hedge funds and other institutional investors have recently bought and sold shares of the company. United Services Automobile Association increased its position in Iovance Biotherapeutics by 31.0% during the 2nd quarter. United Services Automobile Association now owns 14,493 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 3,431 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Iovance Biotherapeutics by 9.9% during the first quarter. Wells Fargo & Company MN now owns 54,832 shares of the biotechnology company’s stock worth $926,000 after purchasing an additional 4,957 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Iovance Biotherapeutics by 61.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,918 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 5,318 shares during the last quarter. Rhumbline Advisers lifted its stake in Iovance Biotherapeutics by 7.7% in the second quarter. Rhumbline Advisers now owns 76,424 shares of the biotechnology company’s stock valued at $978,000 after buying an additional 5,465 shares during the last quarter. Finally, California Public Employees Retirement System lifted its stake in Iovance Biotherapeutics by 5.6% in the second quarter. California Public Employees Retirement System now owns 105,440 shares of the biotechnology company’s stock valued at $1,350,000 after buying an additional 5,598 shares during the last quarter. 87.51% of the stock is owned by institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Featured Article: Using the New Google Finance Tool

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply